Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine

Yue-Mei Hu; Shou-Jie Huang; Kai Chu; Ting Wu; Zhong-Ze Wang; Chang-Lin Yang; Jia-Ping Cai; Han-Min Jiang; Yi-Jun Wang; Meng Guo; Xiao-Hui Liu; Hong-Jiang Huang; Feng-Cai Zhu; Jun Zhang; Ning-Shao Xia
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • A cervical cancer vaccine comes closer to reality. Kristen, Georgi // Patient Care;Dec2004, Vol. 38 Issue 12, p9 

    Discusses research being done on the efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women. Reference to a study by D. M. Harper et al published in the 2004 issue of "Lancet"; Findings of the study.

  • Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like.... Harro, Clayton D.; Pang, Yuk-Ying Susana; Roden, Richard B.S.; Hildesheim, Allan; Zhaohui Wang; Reynolds, Mary Jane; Mast, T. Christopher; Robinson, Robin; Murphy, Brian R.; Karron, Ruth A.; Dillner, Joakim; Schiller, John T.; Lowry, Douglas R. // JNCI: Journal of the National Cancer Institute;02/21/2001, Vol. 93 Issue 4, p285 

    Examines the immunogenicity of human papillomavirus type 16 L1 virus-like particle among adults. Vaccine formulations; Dependence of serum antibody responses on dosage.

  • Prophylactic HPV vaccines. Mandić, Aljoša // Archive of Oncology;2009, Vol. 17 Issue 3/4, p68 

    Human papillomavirus (HPV) is one of the most common sexually transmitted diseases worldwide. Cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis are HPVassociated diseases. Prophylactic HPV vaccines are...

  • Profilaktik HPV aşıları: güncel yaklaşımlar. Dede, Murat // Gulhane Medical Journal;Jun2010, Vol. 52 Issue 2, p148 

    The recognition of a strong etiological relationship between infection with high-risk human papillomaviruses and cervical cancer has prompted research to develop and evaluate prophylactic and therapeutic vaccines. One prophylactic quadrivalent vaccine using L1 virus-like particles (VLP) of HPV6,...

  • Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz, Lauri E.; Dunne, Eileen F.; Saraiya, Mona; Chesson, Harrell W.; Curtis, C. Robinette; Gee, Julianne; Bocchini, Jr, Joseph A.; Unger, Elizabeth R. // MMWR Recommendations & Reports;8/29/2014, Vol. 63 Issue 5, p1 

    This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and post-licensure safety studies, and compiles recommendations from CDC’s Advisory Committee on Immunization...

  • Update of human papillomavirus vaccination. Byoung-Gie Kim // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Apr2015, Vol. 58 Issue 4, p313 

    Infection with one of 15 types of high-risk human papillomavirus (HPV) is the cause of cervical cancer . Worldwide, 70% of cervical cancer is caused by either HPV type 16 or 18. The current HPV vaccine is composed of virus-like particles (VLPs) of the L1 capsid protein as well as adjuvant....

  • Researchers find HPV vaccine safe, effective for 4.5 years.  // Contemporary OB/GYN;Jun2006, Vol. 51 Issue 6, p17 

    Discusses a research on the sustained efficacy of a bivalent L1 virus-like particle vaccine against HIV types 16 and 18. Reference to a study by D. M. Harper et al, published in a 2006 issue of "The Lancet"; Efficacy of the vaccine against incident infection; Discrepancies in the research findings.

  • New biologics.  // Formulary;Jul2006, Vol. 41 Issue 7, p306 

    The article provides information on Gardasil, an approved quadrivalent human papillomavirus recombinant vaccine for the prevention of cervical cancer from Merck. Gardasil is prepared from the virus-like particles of the major capsid protein of the human papillomavirus. Safety, efficacy, and...

  • Comparing the HPV vaccines. Blamble, Deborah // Infectious Disease News;Apr2010, Vol. 23 Issue 4, p53 

    The article presents a discussion about the different types of human papillomavirus (HPV) vaccines, which include quadrivalent and bivalent.

  • HPV vaccines in Brazil and the world. Villa, Luisa // BMC Proceedings;10/1/2014, p1 

    The article presents research on human papillomavirus (HPV) vaccines in Brazil and the rest of the world. Topics discussed include the types of high-risk HPV, the development of HPV vaccines, the virus-like particles self-assenbly, HPV vaccine implementation, and the successs of prophylactic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics